Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses

Vaccine

Volumn 16, Issue 8, 1998, Pages 823-833

  Oseroff, Carla ^a   Sette, Alessandro ^a   Wentworth, Peggy ^c   Celis, Esteban ^c   Maewal, Ajesh ^a   Dahlberg, Carol ^a   Fikes, John ^a   Kubo, Ralph T ^c   Chesnut, Robert W ^a   Grey, Howard M ^b   Alexander, Jeff ^a  

^a Epimmune   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c CYTEL CORPORATION   (United States)

Author keywords

CTL response; Lipidated peptides; Multiple epitopes

Indexed keywords

EPITOPE; FREUND ADJUVANT; HLA A2 ANTIGEN; LIPOPEPTIDE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE CONSTRUCT; HELPER CELL; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; EPITOPES; FEASIBILITY STUDIES; HEPACIVIRUS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; MICE; MICE, INBRED A; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PALMITIC ACID; PEPTIDE FRAGMENTS; SODIUM CHLORIDE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

EID: 17344386915     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00264-8     Document Type: Article

References (69)

1. 1 Chesnut, R.W., Sette, A. and Celis, E. et al. Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutic to treat infectious diseases and cancer. In: Vaccine Design, Vol. 6 (Eds Powell, M.F. and Newman, M.J.). Plenum Press, New York, 1995, pp. 847-874.
2. 2 van der Most, R.G., Sette, A. and Oseroff, C. et al. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection J. Immunol. 1996, 157, 5543-5554.
3. 3 Chisari, F.V. and Ferrari, C. Immunopathogenesis of hepatitis B virus. Annu. Rev. Immunol. 1995, 13, 29-60.
4. 4 Boon, T., Cerottini, J., Van den Eynde, B., van der Bruggen, P. and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994, 12, 337-365.
5. 5 Germain, R.N. and Margulies, D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 1993, 11, 403-450.
6. 6 Engelhard, V.H. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 1994, 12, 181-207.
7. 7 Rammensee, H.-G., Falk, K. and Rötzschke, O. Peptides naturally presented by MHC Class I molecules. Annu. Rev. Immunol. 1993, 11, 213-244.
8. 8 McMicheal, A.J. and Phillips, R.E. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 1997, 15, 271-296.
9. 9 Diepolder, H.M., Gerlach, T. and Zachoval, R. et al. The CD4+ T lymphocyte response to the hepatitis C virus nonstructural protein 3 (NS3) in resolving acute hepatitis C focuses on a single, promiscuous 14-amino-acid peptide. J. Virol. 1997, 6011-6019.
10. 10 Doolan, D. L., Hoffman, S.L. and Southwood, S. et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and -B supertype alleles. J. Immunity 1997, 7, 97-122.
11. 11 Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A. and McGuire, W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
12. 12 Thompson, J., Grunert, F. and Zimmerman, W. CEA gene family: molecular biology and clinical perspectives. J. Clin. Lab Anal. 1991, 5, 344-366.
13. 13 Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J. and Schlom, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst. 1992, 84, 1084-1091.
14. 14 Russo, V., Traversari, C., Verrecchia, A., Mottolese, M., Natali, P.G. and Bordignon, C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int. J. Cancer 1995, 64, 216-221.
15. 15 Disis, M.L., Gralow, J.R., Bernhard, H., Hand, S.L., Rubin, W.D. and Cheever, M.A. Peptide based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J. Immunol. 1996, 156, 3151-3158.
16. - T cell-, interferon γ-nitric oxide-dependent immunity . Exp. Med. 1996, 183, 1739-1746.
17. b-restricted epitopes. J. Immunol. 1996, 157, 5555-5562.
18. 18 Tsai, V., Southwood, S. and Sidney, J. et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 1997, 158, 1796-1802.
19. 19 Vitiello, A., Sette, A. and Yuan, L. et al. Comparison of CTL responses induced by peptide DNA immunization: implications on immunogenicity and immunodominance. Eur. J. Immunol. 1977, 27, 671-678.
20. 20 Oukka, M., Manuguerra, J.C. and Livaditis, N. et al. Protection against lethal viral infection by vaccination with non-immunodominant peptides. J. Immunol. 1996, 157, 3039-3045.
21. 21 Franke, E.D., Sacci, J. Jr., Corradin, G., Sette, A., Southwood, S. and Hoffman, S.L. CD8+ CTL epitope on the Plasmodium yoelli circumsporozoite protein: induction of CTL by immunization with branched chain, multiple antigenic peptide, but not by linear synthetic peptide, DNA plasrnid or attenuated parasite immunization. (Unpublished).
22. 22 Sette, A., Alexander, J. and Appella, E. et al. The use of synthetic peptides to characterize CTL responses in acute and chronic viral diseases. In: Persistent Viral Infections (Eds Ahmed, R. and Chen, I.). John Wiley and Sons (in press).
23. 23 Parkhurst, M.R., Salgaller, M. and Southwood, S. et al. Efficient induction of melanoma reactive CTL with peptides modified at HLA-A*0201 binding residues from the melanoma antigen, gp100. J. Immunol. 1996, 157, 2539-2548.
24. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 1996, 183, 1965-1972.
25. 25 Livingston, B.D., Crimi, C. and Grey, H. et al. The Hepatitis B virus-specific CTL responses induced in human by lipopetide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159 (in press).
26. 26 Alexander, J., Sidney, J. and Southwood, S. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1, 751-761.
27. 27 Vitiello, A., Ishioka, G. and Grey, H.M. et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: I. Induction of a primary CTL response in man. J. Clin. Invest. 1995, 95, 341-349.
28. 28 Barber, L.D., Gillece-Castro, B., Percival, L., Li, X., Clayberger, C. and Parham, P. Overlap in the repertoires of peptides bound in vivo by a group of related Class I HLA-b allotypes. Curr. Biol. 1995, 5, 179-190.
29. 29 Sidney, J., del Guercio, M.-F. and Southwood, S. et al. Several HLA alleles share overlapping peptide specificities. J. Immunol. 1995, 154, 247-259.
30. 30 Sidney, J., Grey, H.M. and Southwood, S. et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide binding repertoires of common HLA molecules. Human. Immunol. 1996, 45, 79-93.
31. 31 Rivoltini, L., Loftus, D.J. and Barracchini, K. et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. J. Immunol. 1996, 156, 3886-3891.
32. l cytotoxic T cell line. J. Immunol. 1996, 157, 787-797.
33. 1 Helix of the HLA-B heavy chain can have an overriding influence on peptide binding specificity. J. Immunol. 1997, 158, 1660-1669.
34. 34 Sidney, J., Southwood S. and del Guercio M.F. et al. Specificity and degeneracy in peptide binding to HLA-B7-like Class I molecules. J. Immunol. 1996, 157, 3480-3490.
35. 35 Sidney, J., Grey, H.M., Kubo, R.T. and Sette, A. Practical, biochemical and evolutionary implications of the discovery of HLA Class I supermotifs. Immunol. Today 1996, 17, 261-266.
36. 36 Griffiths, J.C., Harris, S.J. and Layton, G.T. et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 1993, 67, 3191-3198.
37. 37 Martin, S.J., Vyakarnam, A. and Cheinsong-Popov, R. et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24: ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS 1993, 7, 1315-1323.
38. 38 Deres, K., Schild, H., Weismuller, K.H., Jung, G. and Rammensee, H.G. In vivo priming of the virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342, 561-564.
39. 39 BenMohamed, L., Gras-Masse, H. and Tatar, A. et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 1997, 27, 1242-1253.
40. 40 Eldridge, J.H., Staas, J.K., Meulbroek, J.A., McGhee. J.R., Tice, T.R. and Gilley, R.M. Biodegradable microspheres as a vaccine delivery system. Molec. Immunol. 1991, 28, 287-294.
41. 41 Alonso, M.J., Gupta, R.K., Min, C., Siber, G.R. and Longer, R. Biodegradable microspheres as controlled release tetanus toxoid delivery systems. Vaccine 1994, 12, 299-306.
42. 42 Jones, D.R., McBride, B.W., Jeffery H., O'Ragarr, O.T., Robinson, A. and Farrar, G.H. Protection of mice from Bordella pertussis respiratory infection using microencapsulated pertussis fimbriae. Vaccine 1995, 13, 675-681.
43. + cytotoxic T cells by immunization with purified HIV-1 envelope epitope protein in ISCOMS. Nature 1990, 344, 873-875.
44. 44 Reddy, R., Zhou, F., Nair, S., Huang, L. and Rouse, B.T. In vivo cytotoxic lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 1992, 148, 1585-1589.
45. 45 Sauzet, J.P., Gras-Masse, H., Guillet, J. and Gomard, E. Influence of strong CD4 epitope on long term virus-specific cytotoxic T cell responses induced in vivo with peptides. International Immunol. 1996, 8, 457-465.
46. + cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Vaccine 1995, 13, 1669-1676.
47. 47 Whitton, J.L., Sheng. N., Oldstone, M.B.A. and McKee, T.A. A s̀tring-of-beads' vaccine, comprising linked minigenes, confers protection from lethal dose virus challenge. J. Virol. 1993, 67, 348-352.
48. 48 Thompson, S.A., Elliot, S.L. and Sherritt, M.A. et al. Recombinant polyepiotpe vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 1996, 157, 822-826.
49. 49 Ciernik, F., Berzotsky, J.A. and Carbone, D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cells epitopes. J. Immunol. 1996, 156, 2369-2375.
50. 50 Atherton, E. and Sheppard, R.C. Fluorenylmethoxycarbnyl-polyamide solid phase peptide synthesis - general principles and development. In: Solid Phase Peptide Synthesis: A Practical Approach. IRL Press, Eynsham, Oxford, 1989, pp. 25-37.
51. 51 Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 1989, 19, 2237-2242.
52. 52 Bertoletti, A., Ferrari, C. and Fiaccadori, F. et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl Acad. Sci. USA 1991, 88, 10445-10449.
53. 53 Rehermann, B., Lau, O., Roolnagie, J. and Chisari, F.V. Cytotoxic T lymphocyte responsiveness after resolution of chronic Hepatitis B virus infection. J. Clin. Invest. 1996, 97, 1655-1665.
54. 54 Nayersina, R., Fowler, P. and Guillert, S. et al. HLA A2 restricted cytotoxic T lymphocyte response to multiple Hepatitis B surface antigen epitopes during Hepatitis B virus infection. J. Immunol. 1993, 150, 4659-4671.
55. 55 Cerny, A., McHutchinson, J.G. and Pasquinell, C. et al. Cytotoxic T lymphocyte response to Hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 1995, 95, 521-530.
56. 56 Shirai, M., Okada, H. and Nishika, M. et al. An epitope in Hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J. Virol. 1994, 68, 3334-3342.
57. 57 Missale, G., Redeker, A. and Person, J. et al. HLA-A31-and HLA-Aw68-restricted cytotoxic T cell responses to a single Hepatitis B virus nucleocapsid epitope during acute viral Hepatitis. J. Exp. Med. 1993, 177, 751-762.
58. b transgenic mice. Functional CTL repertoire and recognition of human all restricted (TL epitopes. J. Immunol. 1997, 159, 4753-4761.
59. 59 Shimizu, Y. and DeMars, R. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J. Immunol. 1989, 142, 3320-3328.
60. 60. Shirai, M., Chen, M. and Arichi, T. et al. Use of intrinsic and extrinsic helper epitope for in vivo induction of anti-Hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 1996. 173, 24-31.
61. 61 Vitiello, A., Marchesini, D., Furze, J., Sherman, L. and Chesnut, R.W. Analysis of the HLA restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human mouse Class I major histocompatibility complex. J. Exp. Med. 1991, 173, 1007-1015.
62. 62 Wentworth, P.A., Vitiello, A. and Sidney, J. et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 1996, 26, 97-101.
63. 63 Irwin, M.J., Heath, W.R. and Sherman, L.A. Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of xenogeneic response. J. Exp. Med. 1989, 170, 1091-1101.
64. 64 Borges, E., Weismüller, K.-H., Jung, G. and Waiden, P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes: comparison of the costimulating support provided by helper T cells and lipoamino acid. J. Immunol. Meth. 1994, 173, 253-263.
65. 65 Nardelli, B., Haser, P.B. and Tam, J.P. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine 1994, 12, 1335-1339.
66. 66 Rouaix, F., Gras-Masse, H. and Mazingue, C. et al. Effect of the lipopeptidic formulation on macrophage activation and peptide presentation to T cells. Vaccine 1994, 12, 1209-1214.
67. 67 Deprez, B., Suazet, J.-P. and Boutillon, C. et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996, 14, 375-382.
68. 68 Ressing, M.E., Sette, A. and Brandt, R.M.P. et al. Human CTL epitopes derived from the human papilloma virus type 16 E6 and E7 proteins identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 1995, 154, 5934-5943.
69. + cytotoxic T cells: implications for vaccine design. Proc. Natl Acad. Sci. 1995, 92, 5845-5849.